• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
PTH - Chronic Renal Failure
 

PTH - Chronic Renal Failure

on

  • 9,625 views

FREE Medical eBooks => http://asgarcymed.blogspot.com/

FREE Medical eBooks => http://asgarcymed.blogspot.com/

Statistics

Views

Total Views
9,625
Views on SlideShare
9,599
Embed Views
26

Actions

Likes
1
Downloads
278
Comments
0

2 Embeds 26

http://www.slideshare.net 22
http://asgarcymed.blogspot.com 4

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

PTH - Chronic Renal Failure PTH - Chronic Renal Failure Presentation Transcript

    • Learning Objectives:
    • Describe the physiology of PTH and mineral metabolism in patients with CKD
    • Discuss the available therapies for the disorders of PTH and mineral metabolism in patients with CKD
    • Apply this information to the clinical management of patients with CKD
    PTH and Mineral Disorders in Patients With CKD: A Practical Case-Based Approach for Renal Dietitians
  • Patient Case
    • 53-year-old male with history of stage 5 CKD 2 º AD PKD recently started on hemodialysis after failed renal transplant
    • History of deceased donor renal transplant, 11/95
    • Previously on hemodialysis, 6/95–11/95
    • History of CVD, s/p CABG x 3 in 02/04
    • History HTN; history basal cell carcinoma
    • Social history: works as car mechanic; no history of alcohol, tobacco; married 21 years; 1 daughter, age 19
    • Family history ADPKD on maternal side
  • Patient Case (cont)
    • Presents with mild itching, bone pain
    • No history of fractures
    • Medications:
      • Calcium acetate: 667 mg 3 tab tid
      • B-complex with C: 1 tab qd
      • Atorvastatin: 20 mg qd
      • Metoprolol: 50 mg bid
      • Prednisone: 2.5 mg qd
    • Laboratory values:
      • Phosphorus: 8.0 mg/dl
      • Corrected calcium: 8.3 mg/dl
      • Intact PTH: 670 pg/ml
      • Ca x P: 66.4
    • Concentration in blood/plasma is tightly regulated by PTH and vitamin D
    • Calcium ions serve a variety of functions
      • Signal transduction: 1st and 2nd messengers
      • Nerve and muscle function
      • Major component of bone
    • Serum calcium does not reflect total body calcium content
    Overview of Calcium Physiology
  • Regulation of Plasma Calcium Adapted from E Nemeth. PT glands CaSR PTH bone PO 4 reabsorption Ca reabsorption kidney PT glands CaSR PO 4 resorption Ca resorption Low plasma Ca 2+ plasma Ca 2+ intestine 1,25-dihydroxy- vitamin D 3 PO 4 absorption Ca absorption
  • Liver Kidney Skin Pre-vitamin D Vitamin D 7-dehydrocholesterol 25-OH calcidiol 1  -hydroxylase 1,25 (OH) 2 D calcitriol most potent metabolite Low PO 4 Low Ca High PTH + - High PO 4 High Ca Low PTH Vitamin D Metabolism Diet Adapted from WG Goodman.
  • Principal Biological Effects of Vitamin D
    • Increases absorption of Ca and P
    • Maintains bone mineralization and turnover
    • Indirectly reduces synthesis of calcitriol
    • Reduces synthesis of PTH
  • Acute and Chronic Regulation of PTH Output Ca 2+ /CaSR PO 4 weeks, months, years Tissue hyperplasia Vit D / VDR  VDRE Ca 2+  CaRE low Ca ( ↑ half-life) low PO 4 ( ↓ half-life) hours, days Gene expression Transcription mRNA stability Ca 2+ /CaSR minutes PTH secretion FACTORS TIME FRAME PROCESS
  • Phosphorus Metabolism
    • Normal PO 4 levels in plasma: 2.5–4.5 mg/dL 1
    • Total body PO 4 content: 500–700 g 1 (85% in bone)
    • Dietary Reference Intake 2 : 700 mg
    • Typical US dietary intake 2 : 1200 mg
    • GI absorption
      • Mainly passive, through Na/Pi transporter
      • Fractional absorption 60–70%
      • Enhanced by vitamin D
    • Kidney is major regulator 3
      • Mediated by brush border Na/Pi transporter
      • PTH – increases excretion 
      • Vitamin D – decreases excretion
    1. Merck Manual . 2006;Sec 2:Ch 12. 2. Food & Nutrition Board, Institute of Medicine. Washington D.C.: National Academy Press; 1997:146-189. 3. Takeda E, et al. Adv Enzyme Regul . 2000;40:285-302.
  • Phosphorus Homeostasis 1200 mg 500 mg 130 mg 700 mg (< 1%) (85%) (15%) Soft tissues Plasma Bone Kidney Intestine 700 mg Adapted from: Goodman WG. Med Clin North Am . 2005;89:631-647.
  • Physiology Summary
    • PTH and vitamin D are central regulators of plasma Ca
    • Calcium regulates serum PTH through the parathyroid CaSR
    • PTH production is controlled at several levels:
    • Kidney is crucial for calcitriol synthesis and phosphate secretion
    • Calcitriol increases serum calcium through increased intestinal absorption
    Hyperplasia mRNA level Secretion Vitamin D Calcium
  • Secondary HPT Pathophysiology: Overview
    • CKD disrupts calcium homeostasis
      • High PTH
      • Low calcitriol
      • Reduced intestinal calcium absorption
      • Low serum calcium at low GFR
      • High serum phosphorus at low GFR
    • Excess PTH synthesis and secretion
      • Inhibition of PTH transcription is deficient
      • Hyperplasia and parathyroid gland enlargement contribute to elevated serum PTH
  • Serum Analytes Vary With Stage of Kidney Disease
    • Craver L, et al. Nephrol Dial Transpl . 2007;22:1171-1176.
    • .
    50 40 30 20 10 0 CKD1 CKD2 CKD3 CKD4 CKD5 N = 15 87 221 156 43 1,25-(OH) 2 D (pg/mL) i PTH (pg/mL) CKD1 CKD2 CKD3 CKD4 CKD5 N = 174 341 856 354 111 0 200 100 * * * * * * * * P < 0.05 LLN ULN LLN
  • Serum Analytes Vary With Stage of Kidney Disease (cont)
    • Craver L, et al. Nephrol Dial Transpl . 2007;22:1171-1176.
    CKD1 CKD2 CKD3 CKD4 CKD5 N = 174 341 856 354 111 9.7 9.6 9.5 9.4 9.3 9.2 9.1 9.0 8.9 Serum Calcium (mg/dL) CKD1 CKD2 CKD3 CKD4 CKD5 N = 174 341 856 354 111 Serum Phosphate (mg/dL) 5.5 5.0 4.5 4.0 3.5 3.0 * * P < 0.05 * * All calcium values within normal range ULN
  • Pathophysiology of sHPT in CKD Adapted from Skorecki K, et al. Harrison’s Principles of Internal Medicine . 15th ed. 2001:1551-1562. ↓ 1,25(OH) 2 D 3 ↑ P ↑ PTH ↓ Ca 2+
  • Risk of Death by Quarterly Varying iPTH 1 1.5 2 0.9 All-Cause Death Hazard Ratio Serum iPTH (pg/mL) KDOQI recommended range: 150-300 pg/mL < 100 100-200 200-300 300-400 400-500 500-600 600-700  700 Time-dependent Case-Mix and MICS model Kalantar-Zadeh K, et al. Kidney Int. 2006;70:771-780.
  • Corrected Serum Calcium (mg/dL) < 8.0 8.0 to 8.5 8.5 to 9.0 9.0 to 9.5 9.5 to 10.0 10.0 to 10.5 10.5 to 11  11.0 0.7 2 3 1 All-Cause Death Hazard Ratio 8.0 to 0.7 2 3 1 0.7 2 3 1 0.7 1.5 2 3 1 Risk of Death by Quarterly Varying Albumin-Adjusted Calcium KDOQI recommended range 8.4-9.5 mg/dL Time-dependent Case-Mix and MICS model Kalantar-Zadeh K, et al. Kidney Int. 2006;70:771-780.
  • Risk of Death by Quarterly Varying Phosphorus Serum Phosphorus (mg/dL) 2 3 4 1 2 3 4 1 2 3 4 1 < 3.0 3.0 to 3.99 4.0 to 4.99 5.0 to 5.99 6.0 to 6.99 7.0 to 7.99 8.0 to 8.99  9.0 KDOQI recommended range: 3.5-5.5 mg/dL All-Cause Death Hazard Ratio Kalantar-Zadeh K, et al. Kidney Int. 2006;70:771-780. Time-dependent Case-Mix and MICS model 0.7 2 3 4 1
  • Clinical Consequences of Mineral Dysregulation
    • Renal osteodystrophy
    • Hyperphosphatemia
    • Cardiovascular calcification
    • Extraskeletal calcification
    • Endocrine disturbances
    • Neurobehavioral changes
    • Compromised immune system
    • Altered erythropoiesis
  • Forms of Vascular Calcification London GM et al. Curr Opin Nephrol Hypertens. 2005;14:525–531. Arterial Calcification Intimal Calcification Atherosclerosis Stenosis, occlusions Infarction, ischemia Medial Calcification Arteriosclerosis Stiffening Systolic and pulse pressures, early return of wave reflections Altered coronary perfusion, left-ventricular hypertrophy
  • Risk Factors for Soft Tissue Calcification
    • Hyperphosphatemia
    • Increased Ca x P product
    • Excessive calcium load
    • Secondary hyperparathyroidism
    • Local tissue injury
    • Rise in tissue pH
    • Decreased levels of calcification inhibitors
    • Systolic hypertension (average 1 year systolic bp 160 mm Hg vs 120)
    • Adipose tissue (calcific uremic arteriolopathy)
  • Vascular Calcification in ESRD Intimal Calcification Atherosclerosis Medial Calcification Arteriosclerosis Available at: http://library.med.utah.edu/WebPath/CVHTML/CV007.html. Accessed May 2007.
  • Impact of Arterial Calcification in Stable Hemodialysis Patients with ESRD London GM, et al. Nephrol Dial Transplant. 2003;18:1731. Cardiovascular Survival  2 = 34.9; P < 0.0001 Time (months) NC P < 0.01 P < 0.001 AMC AIC  2 = 44.3; P < 0.00001 All-Cause Survival NC P < 0.001 P < 0.01 AMC AIC 0 25 50 75 100 0.00 0.75 0.50 0.25 1.00 0 25 50 75 100 0.00 0.75 0.50 0.25 1.00
  • Probability of Survival Decreases With Increasing Arterial Calcification 0 0.25 0.5 0.75 1 0 20 40 60 80 Follow-up (months) Probability of Survival 0 Arteries Calcified 1 Artery Calcified 2 Arteries Calcified 3 Arteries Calcified 4 Arteries Calcified N = 110 stable dialysis patients with ESRD P < 0.0001 comparison among groups Blacher J, et al. Hypertension . 2001;38:938-942.
  • Valvular Calcification and Mortality † P < 0.0005 vs no valvular calcification 0 0.2 0.4 0.6 0.8 1.0 0 6 12 18 24 30 36 Overall Survival Both Mitral and Aortic (n = 14) Either Mitral or Aortic (n = 48) Neither (n = 130) Follow-Up Time (months) † Wang A, et al. J Am Soc Nephrol. 2003;14:159-168.
  • CAC Is Associated With Increased Mortality Block GA, et al. Kidney Int . 2007;71:438-441. 0 6 12 18 CAC = 0 CAC1 – 400 CAC  400 24 0.00 0.25 0.50 0.75 1.00 30 36 42 48 54 60 66 P = 0.002 Months Survival Distribution Function
  • Calcification in Vascular Smooth Muscle Cells Osteo/Chondrocytic VSMC Death Signal VSMC Damage “Uremic Milieu” Apoptotic Bodies Matrix Vesicles + MGP / BMP7 + fetuin-A + PPi - MGP/ BMP2 - fetuin-A - PPi/+ALK + Ca/P Clearance Calcification Phagocytosis Delayed or Impaired Phagocytosis Elastin Shanahan CM. Curr Opin Nephrol Hypertens. 2005 ; 14:361–367.
  • Vascular Calcification, Cardiovascular Complications, and CKD
    • Vascular Calcification Associated With:
      • Accelerated risk of stroke, amputation, MI
      • Left ventricular hypertrophy
      • Poor coronary artery perfusion
      • Increased pulse wave velocity
      • Increased pulse pressure
    • Contributory Factors:
      • Deranged bone and mineral metabolism
      • Decreased levels of inhibitors of calcification such as fetuin-A
      • Stimulation of osteogenic pathways in endothelial cells by uremic “toxins”
      • Impaired endothelial repair mechanisms
    Adapted from Lederer E and Ouseph R. Am J Kidney Dis. 2007;49:162-171. Block GA, et al. Kidney Int. 2007;71(5):438-441.
  • KDOQI ™ Goals for Stage 5 CKD National Kidney Foundation. Am J Kidney Dis . 2002;39(Suppl 1):S1-S266. KDOQI guidelines recommend that Ca 2+ and P should be monitored monthly and PTH quarterly after stabilization. < 55 mg 2 /dL 2 Ca x P Product 3.5 – 5.5 mg/dL Serum P 8.4 – 9.5 mg/dL Serum Ca (albumin-corrected) 150 – 300 pg/mL Serum PTH
  • Patient Case Review/Update
    • Medications:
      • Calcium acetate: 667 mg 3 tab tid
      • B-complex with C: 1 tab qd
      • Atorvastatin: 20 mg qd
      • Metoprolol: 50 mg bid
      • Prednisone: 2.5 mg qd
    • Laboratory values:
      • Phosphorus: 8.0 mg/dl
      • Corrected calcium: 8.3 mg/dl
      • Intact PTH: 670 pg/ml
      • Ca x P: 66.4
  • Nutrition Guidelines
    • Limit dietary phosphorus to 800-1000 mg/d with consideration for protein needs, ie, as low as possible while allowing for a recommended level of protein intake
    • Limit elemental calcium from calcium-based binders to ≤ 1500 mg/d
    • Limit total (dietary and medication) elemental calcium to ≤ 2000 mg/d
    • Avoid calcium fortified foods as directed
    • Moderate application of cardiovascular dietary recommendations, not to the detriment of nutrition status
    National Kidney Foundation. Am J Kidney Dis . 2002;39(Suppl 1):S1-S266.
  • Lifestyle Guidelines
    • Exercise training
    • Identify and address psychological issues (eg, depression)
    • No smoking (help prevent CVD?)
  • Patient Case Review/Update
    • Patient started on sevelamer HCl 800 mg 2 tablets tid with meals, Ca acetate discontinued to reduce vascular calcification risk
    • Repeat labs after 2 weeks:
      • Phosphorus: 6.5 mg/dl
      • Corrected calcium: 8.3 mg/dl
      • Ca x P: 54
    • Diet reviewed; sevelamer increased to 3 tablets with meals, 2 tablets with snacks
  • Therapeutic Interventions for Managing Secondary HPT Intervention Result Ca PO 4 PTH Phosphate Binders (Ca-based) Adapted from Goodman WG. Nephrol Dial Transplant. 2003;18(suppl 3):iii2-iii8.
  • Managing Mineral Balance: Phosphate Binders Sevelamer label: http://www.renagel.com/docs/renagel_pi.pdf Block GA, et al. Kidney Int. 2007;71(5):438-441. Serum Phosphate Sevelamer Calcium Mortality Phosphorus Change Study Week 0 2 6 10 14 18 22 26 30 34 38 42 46 52 -5 -4 -3 -2 -1 0 1 2 1.00 0.75 0.50 0.25 0.00 0 6 12 18 24 30 36 42 48 54 60 66 P = 0.016 Survival Fraction Sevelamer Calcium Months
  • Use of Phosphate Binders
    • Ca-based binder should not be used if patient has hypercalcemia or PTH < 150 pg/mL
    • Non-Ca-based binder preferred if vascular or soft-tissue calcification is appreciable
    National Kidney Foundation. Am J Kidney Dis . 2002;39(Suppl 1):S1-S266. Al-OH up to 4 wks Ca-based and other binder Dietary P restriction, Ca-based or other binder Stage 5 Ca-based binder Dietary P restriction Stage 3/4 3 rd line 2 nd line 1 st line
  • Phosphate Binders: Summary Cannata-Andia JB. Dial Trans . 2002;17(Suppl 11):16–19; Ritz EJ. J Nephrol. 2005;18;221-228. Goodman WG. Neph Dial Trans. 2003;18(Suppl 3):iii2-iii8; Block GA, et al. Kidney Int. 2007; 71(5):438-441. Hyper-Mg; no long term studies Potential to minimize Ca load Magnesium carbonate Cost; Taste fatigue; Unknown long term impact; Tolerability Good potency; Minimal absorption; Not Hyper-Ca; Low pill burden Lanthanum carbonate High pill burden (moderate potency); Cost; Tolerability Less vascular calcification than Ca-containing binders; lower mortality? Reduction of TC & LDL Sevelamer Hyper-Ca, calcification risk; High pill burden Effective; Widely used Calcium-containing Tissue accumulation; Bone disease, encephalopathy, anemia Effective Aluminum-containing Disadvantages Advantages Binder
    • At 1 month, labs are checked
      • Phosphorus: 5.5 mg/dL
      • Corrected calcium: 8.3 mg/dL
      • Ca x P: 46
      • Intact PTH: 601 pg/mL
      • 25-hydroxy vitamin D: 18 ng/mL
    • Started on Vitamin D
      • Ergocalciferol: 50,000 IU/month
      • Active analog
    Patient Case Update
  • Therapeutic Interventions for Managing Secondary HPT Intervention Result Ca PO 4 PTH Vitamin D analog Adapted from Goodman WG. Nephrol Dial Transplant. 2003;18(suppl 3):iii2-iii8.
  • Vitamin D Repletion in Stage 3 & 4 with Ergocalciferol: KDOQI TM Recommendation National Kidney Foundation. Am J Kidney Dis. 2003;42(4 suppl 3):S1-S201. 50,000/mo 50,000/wk X 4 wks, then monthly 500,000 once 50,000/wk X 12 wks; then monthly Dose (IU) Assure pt adherence; assay 25(OH)D at 6 months im 6 po Insufficiency 16-30 Assay 25(OH)D after 6 months 6 po Mild deficiency 5-15 Assay 25(OH)D after 6 months 6 po Severe deficiency < 5 Comment Duration (months) Route Vitamin D Status Serum 25(OH)D (ng/mL)
  • Vitamin D Analogs Suppress PTH Sprague SM, et al. Kidney Int. 2003;63:1483-1490. Time (weeks) PTH (pg/mL) 0 100 200 300 400 500 600 700 800 900 1000 Paricalcitol (n = 130) Calcitriol (n = 133) 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34
  • Vitamin D Use Is Associated With Decreased Mortality in Incident HD Patients Vitamin D (n = 37,173) No Vitamin D (n = 13,864) Teng M, et al. J Am Soc Nephrol . 2005;16:1115-1125. *P < 0.001 8 15 CV Mortality * * 14 29 0 10 20 30 40 50 2-Year Mortality Mortality per 100 Patient-Years Infectious Cause Mortality 1 3 *
  • Which Vitamin D Do We Use and Why?
    • Calcitriol (Calcijex ® , Rocaltrol ® ) active vitamin D
      • Increased calcium and phosphorus absorption
      • Increased serum levels
      • Loses effectiveness with high serum P
    • Paricalcitol (Zemplar ® ) active vitamin D analog
      • Less calcemic
    • Doxercalciferol (Hectorol ® )
      • Less calcemic
  • Recommended Vitamin D Dosing
    • Serum Ca > 10.2 : stop all D, minimize Ca load
    • Ca = 9.5-10.2: change to non Ca-containing binder
    • Ca < 9.5: continue D or modify with P algorithm
    • P > 6.0: stop vitamin D
    • P = 5.5–6.0: increase binders, decrease Vitamin D
    • P < 5.5: continue or modify using Ca or PTH algorithm
    National Kidney Foundation. Am J Kidney Dis . 2002;39(Suppl 1):S1-S266. IV 4 – 8 mcg Oral 10 - 20 mcg 10 – 15 mcg IV 3.0-5.0 Oral 3-7 < 55 < 5.5 < 10 > 1000 IV 2 – 4 mcg Oral 5 – 10 mcg 6.0 – 10 mcg IV 1.0-3.0 Oral 1-4 < 55 < 5.5 < 9.5 600 – 1000 IV 2 mcg Oral 5 mcg 2.5 – 5.0 mcg IV 0.5 – 1.5 Oral same < 55 < 5.5 < 9.5 300 – 600 Doxercalciferol Paricalcitol Calcitriol Ca x P P Ca PTH
    • Laboratory data in one month:
      • Phosphorus: 6.1 mg/dl
      • Calcium: 9.3 mg/dl
      • Ca x P product: 57
      • Intact PTH: 489 pg/ml
    • Patient started on cinacalcet HCl 30 mg qd
    Patient Case Update
  • Therapeutic Interventions for Managing Secondary HPT Intervention Result Ca PO 4 PTH Calcimimetic Adapted from Goodman WG. Nephrol Dial Transplant. 2003;18(suppl 3):iii2-iii8.
  • Targeting PTH Secretion With Cinacalcet Control Serum PTH (% of maximum) 80 60 40 20 100 0 1.5 0 0.5 1.0 2.0 Extracellular Calcium (mM) Cinacalcet Cinacalcet Increases Calcium Sensitivity [Ca 2+ ] ER [Ca i 2+ ] CaSR PTH PTH PTH Cinacalcet Adapted from Goodman WG, et al. Kidney Int . 1996;50:1834-1844.
  • Cinacalcet is Associated with a Reduction of PTH Block GA, et al. New Engl J Med. 2004;350:1516-1525. P < 0.001 Placebo Cinacalcet Dose titration Efficacy assessment Week PTH level (pg/ml) 800 700 600 500 400 300 200 100 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 ~50% reduction
  • Cinacalcet Enables Patients to Achieve the KDOQI ™ Targets Adapted from Moe SM, et al. Kidney Int. 2005;67:760-771. Median iPTH (pg/mL) KDOQI ™ Target 0 100 200 300 400 500 600 700 Week Cinacalcet HCI Placebo n = 471 n = 663 n = 366 n = 473 B 2 4 6 8 12 14 16 18 20 22 24 26 10 iPTH Week n = 471 n = 663 n = 368 n = 471 B 2 4 6 8 12 14 16 18 20 22 24 26 10 Median Serum Ca (mg/dL) 8.2 8.4 8.8 9.0 9.2 9.6 9.8 10.2 8.6 9.4 10.0 KDOQI ™ Target Serum Calcium n = 410 n = 547 n = 412 n = 555 Week n = 471 n = 662 n = 363 n = 466 B 2 4 6 8 12 14 16 18 20 22 24 26 10 Median Ca x P (mg 2 /dL 2 ) 40 45 50 55 60 65 Ca x P KDOQI ™ Target n = 408 n = 545 n = 363 n = 466 Week n = 471 n = 663 B 2 4 6 8 12 14 16 18 20 22 24 26 10 4.6 4.8 5.0 5.2 5.4 5.6 5.8 6.0 6.2 6.4 Median Serum P (mg/dL) Serum Phosphorus KDOQI ™ Target n = 409 n = 547
  • Cinacalcet Reduction of iPTH for 3 Years Moe SM, et al. Nephrol Dial Transplant . 2005;20:2186-2193. Placebo n = 17 Cinacalcet n = 16
  • Cinacalcet Is Associated With Improved Outcomes Cunningham J, et al. Kidney Int . 2005;68:1793-1800. CV Hospitalization Fractures PTX Mortality Week Event-Free Probability 0 4 8 12 16 20 24 28 32 36 40 44 48 52 0.75 0.95 1.00 Standard - 4.1 events / 100 pt yrs Cinacalcet - 0.3 events / 100 pt yrs 0.90 0.85 0.80 Event-Free Probability Week 0 4 8 12 16 20 24 28 32 36 40 44 48 52 0.75 0.95 1.00 Standard - 6.9 events / 100 pt yrs Cinacalcet - 3.2 events / 100 pt yrs 0.90 0.85 0.80 P = 0.04 Week Event-Free Probability 0 4 8 12 16 20 24 28 32 36 40 44 48 52 0.75 0.95 1.00 Standard – 7.4 deaths / 100 pt yrs Cinacalcet – 5.2 deaths / 100 pt yrs 0.90 0.85 0.80 P = NS P = 0.009 P = 0.005 Week Event-Free Probability 0 4 8 12 16 20 24 28 32 36 40 44 48 52 0.75 0.95 1.00 Standard – 19.7 events / 100 pt yrs Cinacalcet – 15.0 events / 100 pt yrs 0.90 0.85 0.80
  • Therapeutic Interventions for Managing Secondary HPT Diet/nutrition, Phosphate Binders, Vitamin D Ca PO 4 PTH Diet/nutrition, Ca-based P-binders Vitamin D Calcimimetics, Vitamin D Adapted from Goodman WG. Nephrol Dial Transplant. 2003;18(suppl 3):iii2-iii8.
    • Lab values checked at 1 week:
      • Phosphorus: 5.4 mg/dL
      • Corrected calcium: 8.7 mg/dL
    • Patient complains of mild nausea
    • Advised to take cinacalcet with evening meal
    • No other changes made at this time
    Patient Case Update
    • Labs rechecked at 1 month
      • Phosphorus: 5.4 mg/dL
      • Corrected calcium: 8.7 mg/dL
      • Intact PTH: 290 pg/ml
      • Ca x P product: 47
    • Nausea resolved
    • No further changes warranted at present
    Patient Case Update (cont)
  • Developing a Treatment Algorithm
    • Promote patient safety and incorporate strategies for the fewest side effects
    • Be consistent with current, valid research and update regularly as new information is available
    • Reflect team consensus and consider facility needs or limitations
    • Provide a schedule for changes (dose, meds, route of admin)
    • Provide logical, easy steps
    • Allow for therapy response time before making additional changes
    • Minimize paperwork
    • Include mechanism to inform patient and team of progress
    • Define limits and provide mechanism to return management to MD if treatment outside parameters is needed
    • Identify outcome measures and provide tracking mechanisms
  • Therapeutic Options for Secondary HPT: Conclusions
    • New phosphate binders offer options for phosphorus reduction without increasing serum calcium
    • Vitamin D analogs lower PTH and increase bone mineralization, but also raise calcium and phosphorus
    • Cinacalcet can be used to lower PTH despite elevations in calcium and/or phosphorus
    • Dialysis is a critical tool for managing ESRD
    • Parathyroidectomy can be useful for lowering PTH when pharmacologic intervention fails